17. 多系統萎縮症 Multiple system atrophy Clinical trials / Disease details


臨床試験数 : 119 薬物数 : 138 - (DrugBank : 44) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 111

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02008721
(ClinicalTrials.gov)
January 20148/12/2013Progression Rate of MSA Under EGCG Supplementation as Anti-Aggregation-ApproachDouble-blind, Randomised, Placebo-controlled Parallel Group Study to Investigate the Effect of EGCG Supplementation on Disease Progression of Patients With Multiple System Atrophy (MSA)Multiple System AtrophyDrug: EGCG as putative neuroprotective agent;Drug: PlaceboDr. Johannes LevinGerman Center for Neurodegenerative Diseases (DZNE);Deutsche Parkinson Vereinigung;Deutsche Stiftung Neurologie;ParkinsonFonds Deutschland gGmbHCompleted18 YearsN/ABoth92Phase 3Germany
2EUCTR2012-000928-18-DE
(EUCTR)
21/11/201328/06/2013Double blind, randomised, prospective placebo controlled parallel group phase III study to investigate the Effect of EGCG supplementation on disease progression of patients with Multiple System Atrophy (MSA)Double blind, randomised, prospective placebo controlled parallel group phase III study to investigate the Effect of EGCG supplementation on disease progression of patients with Multiple System Atrophy (MSA) - Progression Rate of MSA under EGCG Supplementation as anti-Aggregation-Approach Progression of patients with Multiple System Atrophy (MSA);Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Trade Name: Sunphenon EGCg
INN or Proposed INN: EGCG
Other descriptive name: GREEN TEA LEAF
Hospital of the Ludwig-Maximilians-University of MunichNULLNot RecruitingFemale: yes
Male: yes
86Phase 3Germany